GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Cyclically Adjusted PB Ratio

Ionis Pharmaceuticals (Ionis Pharmaceuticals) Cyclically Adjusted PB Ratio : 7.22 (As of May. 30, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-30), Ionis Pharmaceuticals's current share price is $36.84. Ionis Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $5.10. Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 7.22.

The historical rank and industry rank for Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

IONS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 6.09   Med: 18.97   Max: 46.58
Current: 7.14

During the past years, Ionis Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 46.58. The lowest was 6.09. And the median was 18.97.

IONS's Cyclically Adjusted PB Ratio is ranked worse than
85.78% of 654 companies
in the Biotechnology industry
Industry Median: 1.74 vs IONS: 7.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $2.033. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.10 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ionis Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.87 14.17 6.78 7.54 9.99

Ionis Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.98 7.99 8.86 9.99 8.50

Competitive Comparison of Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Ionis Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=36.84/5.1
=7.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ionis Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.033/131.7762*131.7762
=2.033

Current CPI (Mar. 2024) = 131.7762.

Ionis Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 3.118 100.560 4.086
201409 2.922 100.428 3.834
201412 2.176 99.070 2.894
201503 2.306 99.621 3.050
201506 2.505 100.684 3.279
201509 2.045 100.392 2.684
201512 1.668 99.792 2.203
201603 1.310 100.470 1.718
201606 0.920 101.688 1.192
201609 1.153 101.861 1.492
201612 0.819 101.863 1.060
201703 1.629 102.862 2.087
201706 1.736 103.349 2.214
201709 2.471 104.136 3.127
201712 2.249 104.011 2.849
201803 2.402 105.290 3.006
201806 5.076 106.317 6.292
201809 5.167 106.507 6.393
201812 7.599 105.998 9.447
201903 8.649 107.251 10.627
201906 9.042 108.070 11.026
201909 9.502 108.329 11.559
201912 10.482 108.420 12.740
202003 9.766 108.902 11.817
202006 9.873 108.767 11.962
202009 9.894 109.815 11.873
202012 5.295 109.897 6.349
202103 4.829 111.754 5.694
202106 4.132 114.631 4.750
202109 3.758 115.734 4.279
202112 5.465 117.630 6.122
202203 5.006 121.301 5.438
202206 4.405 125.017 4.643
202209 4.185 125.227 4.404
202212 4.033 125.222 4.244
202303 3.402 127.348 3.520
202306 2.992 128.729 3.063
202309 2.200 129.860 2.232
202312 2.679 129.419 2.728
202403 2.033 131.776 2.033

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ionis Pharmaceuticals  (NAS:IONS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ionis Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Executives
Brian Birchler officer: EVP, Corp and Development Ops C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Patrick R. O'neil officer: SVP, Legal and General Counsel C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier officer: Chief Corp Dev and Cml Officer 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider officer: EVP, Chf Clinical Develop Offc C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Joseph Baroldi officer: Chief Business Officer C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eric Swayze officer: SVP, Research 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia director, officer: Senior Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary officer: Senior Vice President 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen officer: SVP, Finance and CFO 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett officer: Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
B Lynne Parshall director, officer: Executive Vice President, CFO 2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Spencer R Berthelsen director 2855 GAZELLE COURT, CARLSBAD CA 92010
Frederick T Muto director 2855 GAZELLE COURT, CARLSBAD CA 92010